Wednesday, June 10, 2026
🇺🇸 FDA

Intelligence · Patents

Patents expiring in 2044

Annual patent cliff calendar for 2044 — US pharmaceutical patents by expiration date.

Patents
1,766

Quick answer

1,766 indexed pharmaceutical patents have expiration dates in 2044. Browse by soonest expiry with links to assignee companies and related drugs.

  1. US 11885817

    Biomarkers and methods for detection of seizures and epilepsy

    Cognizance Biomarkers, LLC · Granted Tue Jan 30 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 25 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 11884748

    Oral peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory bowel diseases

    Protagonist Therapeutics, Inc. · Granted Tue Jan 30 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 25 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. US 11884930

    Method of inactivating a glucocorticoid receptor gene in an isolated cell

    Sangamo Biosciences, Inc. · Granted Tue Jan 30 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 25 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. US 11885806

    Method for depleting malignant T-cells

    AUTOLUS LIMITED · Granted Tue Jan 30 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 25 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. US 11884925

    Synthetic immunomodulation with a CRISPR super-repressor in vivo

    ARIZONA BOARD OF REGENTS FOR AND ON BEHALF OF ARIZONA STATE UNIVERSITY · Granted Tue Jan 30 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 25 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  6. US 11884656

    Pyrrole derivatives as PLK1 inhibitors

    SENTINEL ONCOLOGY LIMITED · Granted Tue Jan 30 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 25 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  7. US 11884746

    Matriptase and u-plasminogen activator substrates and other cleavable moieties and methods of use thereof

    CytomX Therapeutics, Inc. · Granted Tue Jan 30 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 25 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  8. US 11883468

    Compositions and methods to suppress tumor growth in bone, prevent cachectic muscle loss, and preserve skeletal integrity

    United States Government as represented by the Department of Veterans Affairs · Granted Tue Jan 30 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 25 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  9. US 11884657

    PI-kinase inhibitors with anti-infective activity

    The Regents of the University of California · Granted Tue Jan 30 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 25 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  10. US 11883535

    Liposomal particles, methods of making same and uses thereof

    Northwestern University · Granted Tue Jan 30 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 25 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  11. US 11883420

    Sting agonists for treating bladder cancer and solid tumors

    VENENUM BIODESIGN, LLC · Granted Tue Jan 30 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 25 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  12. US 11883433

    Chimeric antigen receptor comprising anti-mesothelin scFv, and use thereof

    CELLENGENE INC. · Granted Tue Jan 30 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 25 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  13. US 11883408

    Reboxetine to treat narcolepsy

    AXSOME THERAPEUTICS, INC. · Granted Tue Jan 30 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 25 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  14. US 11884944

    Fusion proteins comprising sulfoglucosamine sulfohydrolase enzymes and methods thereof

    DENALI THERAPEUTICS INC. · Granted Tue Jan 30 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 25 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  15. US 11884647

    Compounds and methods for targeting pathogenic blood vessels

    The Regents of the University of California · Granted Tue Jan 30 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 25 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  16. US 11884707

    Compositions for detection, inhibition and imaging of indoleamine 2, 3-dioxygenase 1 (IDO1) and methods of making and using same

    REGENERON PHARMACEUTICALS, INC. · Granted Tue Jan 30 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 25 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  17. US 11883423

    Nucleobase analogue derivatives and their applications

    The Board of Regents of the University of Texas System · Granted Tue Jan 30 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 25 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  18. US 11885807

    Method for depleting malignant T-cells

    AUTOLUS LIMITED · Granted Tue Jan 30 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 25 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  19. US 11883359

    Adapter for use in a planetary mixer

    MEDISCA PHARMACEUTIQUE INC. · Granted Tue Jan 30 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 25 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  20. US 11883431

    T-cells modified to overexpress PHF19

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Tue Jan 30 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 25 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  21. US 11883492

    Combination treatment of chemoresistant cancers

    The Regents of the University of California · Granted Tue Jan 30 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 25 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  22. US 11884740

    Anti-CD20 antibody compositions

    TG Therapeutics, Inc. · Granted Tue Jan 30 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 25 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  23. US 11883432

    Chimeric antigen receptor system with adaptable receptor specificity

    Century Therapeutics, Inc. · Granted Tue Jan 30 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 25 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  24. US 11884715

    Activin receptor type IIB variants and methods of use thereof

    Keros Therapeutics, Inc. · Granted Tue Jan 30 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 25 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  25. US 11884731

    Vedolizumab for the treatment of fistulizing Crohn's disease

    Takeda Pharmaceutical Company Limited · Granted Tue Jan 30 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 25 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  26. US 11883223

    Hepatic inflammation analysis with dynamic PET

    The Regents of the University of California · Granted Tue Jan 30 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 25 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  27. US 11883441

    Compositions and methods for inhibiting seizures

    The Regents of the University of California · Granted Tue Jan 30 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 25 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  28. US 11885861

    3-dimensional representations of post-contrast enhanced brain lesions

    The Board of Regents of the University of Texas System · Granted Tue Jan 30 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 25 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  29. US 11883381

    ASH1L inhibitors and methods of treatment therewith

    THE REGENTS OF THE UNIVERSITY OF MICHIGAN · Granted Tue Jan 30 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 25 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  30. US 11883475

    Infectious Plasmodium sporozoites grown in vitro

    Sanaria Inc. · Granted Tue Jan 30 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 25 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  31. US 11884710

    Peptide compounds and methods of use in wound healing

    The Board of Regents of the University of Oklahoma · Granted Tue Jan 30 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 25 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  32. US 11884920

    Alpha-1 antitrypsin (AAT) RNAi agents, compositions including AAT RNAi agents, and methods of use

    Arrowhead Pharmaceuticals, Inc. · Granted Tue Jan 30 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 25 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  33. US 11883383

    Pharmaceutically acceptable salts of [3-(4- {2-butyl-1-[4-(4-chloro-phenoxy)-phenyl]-1H-imidazol-4-yl} -phenoxy)-propyl]-diethyl-amine

    VTV THERAPEUTICS LLC · Granted Tue Jan 30 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 25 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  34. US 11884736

    Antibodies which bind to glucagon-like peptide 1 receptor (GLP1R)

    REGENERON PHARMACEUTICALS, INC. · Granted Tue Jan 30 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 25 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  35. US 11884672

    Modulators of alpha-1 antitrypsin

    Vertex Pharmaceuticals Incorporated · Granted Tue Jan 30 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 25 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  36. US 11883386

    Prolyl hydroxylase inhibitors and methods of use

    Akebia Therapeutics, Inc. · Granted Tue Jan 30 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 25 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  37. US 11884718

    Potent zika virus-specific and cross-neutralizing monoclonal antibodies to zika and dengue viruses following ZIKV infection or vaccination

    The Government of the United States, as represented by the Secretary of the Army · Granted Tue Jan 30 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 25 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  38. CA 3259391

    POLYTHÉRAPIE ANTI-GARP-TGF-β1/PD-1

    ABBVIE BIOTHERAPEUTICS INC [US] · Granted Thu Feb 01 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Wed Jan 27 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  39. CA 3263005

    POLYPEPTIDES SE LIANT À UN ÉPITOPE SPÉCIFIQUE DU RÉCEPTEUR FC NÉONATAL

    SANOFI SA [FR] · Granted Thu Feb 01 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Wed Jan 27 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  40. CA 3259252

    POLYTHÉRAPIE ANTICANCÉREUSE COMPRENANT UN INHIBITEUR DE FLT3

    RYVU THERAPEUTICS S A [PL] · Granted Thu Feb 01 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Wed Jan 27 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  41. CA 3259243

    POLYTHÉRAPIE ANTICANCÉREUSE COMPRENANT UN INHIBITEUR DE BCL-2

    RYVU THERAPEUTICS S A [PL] · Granted Thu Feb 01 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Wed Jan 27 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  42. CA 3256289

    MÉTHODES PERMETTANT DE FAVORISER LA CROISSANCE DE RATTRAPAGE SAINE

    ABBOTT LAB [US] · Granted Thu Feb 01 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Wed Jan 27 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  43. WO 2024023766

    POLYTHÉRAPIE À BASE D'INHIBITEUR DE P13K

    BERLIN CHEMIE AG [DE] · Granted Thu Feb 01 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Wed Jan 27 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  44. US 11890339

    Nipah virus immunogens and their use

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Tue Feb 06 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 01 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  45. US 11890290

    Topical treatment of wounds with statins and cholesterol for scar reduction

    Northwestern University · Granted Tue Feb 06 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 01 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  46. US 11890306

    Lyophilized compositions comprising fecal microbe-based therapeutic agents and methods for making and using same

    Finch Therapeutics Holdings LLC · Granted Tue Feb 06 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 01 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  47. US 11890281

    SHP2 phosphatase inhibitors and methods of making and using the same

    Relay Therapeutics, Inc. · Granted Tue Feb 06 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 01 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  48. US 11890285

    Combination therapies

    Mirati Therapeutics, Inc. · Granted Tue Feb 06 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 01 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

How many pharma patents expire in 2044?

1,766 published patents in our USPTO index have expiration dates falling in calendar year 2044.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.